AUS
NZ
UK
CA
USA
IND
Highlights
CMS Decision: The U.S. Centers for Medicare & Medicaid Services will provide separate payments for specialized diagnostic radiopharmaceuticals starting in 2025, ensuring equitable access for Medicare patients.
Impact on Telix Products: The new payment structure will apply to Telix's Illuccix® and its pipeline products after their transitional pass-through payment status expires.
Focus on Innovation: Telix's ongoing investment in prostate cancer imaging could lead to greater patient access and tailored treatment options, positioning the company as a leader in the PSMA-PET imaging market.
Telix Pharmaceuticals Limited (ASX:TLX) has announced its approval of the U.S. Centers for Medicare & Medicaid Services (CMS) decision to provide separate payments for specialized diagnostic radiopharmaceuticals for Medicare Fee-for-Service patients in hospital outpatient settings. This ruling marks a significant advancement in equitable access to advanced imaging agents for patients and healthcare providers alike.
Starting in 2025, the separate payments under the Hospital Outpatient Prospective Payment System (OPPS) will be determined based on the Mean Unit Cost (MUC) derived from hospital claims data. This policy applies to any specialized diagnostic radiopharmaceutical exceeding a daily cost threshold of $630 and lacking pass-through status. The new rule aims to ensure consistent reimbursement for Medicare patients following the expiration of the transitional pass-through payment period, enhancing the decision-making process for physicians and patients regarding the selection of clinically relevant diagnostic tools based on evidence of utility rather than solely on reimbursement structures.
For Telix, this change offers increased certainty and consistency in pricing policies across all customer segments, which is particularly beneficial for commercial radiopharmaceutical innovators. Notably, the new separate payment rule will affect Telix's flagship product, Illuccix®, after its pass-through status ends on July 1, 2025. Additionally, it will also extend to Telix's pipeline of investigational diagnostic imaging agents, including TLX007-CDx for prostate cancer imaging, TLX250-CDx (Zircaix®) for kidney cancer, and TLX101-CDx (Pixclara®) for brain cancer imaging—assuming these products receive approval and reimbursement from CMS.
Telix continues to invest heavily in innovation within the prostate cancer imaging sector. If TLX007-CDx is approved in the U.S., Telix would become the only company to offer two PSMA-PET imaging agents, thereby expanding patient access to essential diagnostic tools. This strategic positioning allows for a more tailored approach to patient care, catering to diverse clinical profiles, indications, and eligibility for reimbursement. This may also significantly benefit Medicare patients who are currently required to make copayments in hospital outpatient settings.
